Moteur de recherche d’entreprises européennes
Financement de l’UE (12,3 M €) : UN NOUVEL ANTIBIOTIQUE À GRAM NÉGATIF Hor 20/06/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
UN NOUVEL ANTIBIOTIQUE À GRAM NÉGATIF
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics. Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
| Bioaster Fondation de Cooperation Scientifique | 346 038 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 1 236 314 € |
| Evotec International GmbH | 0,00 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 269 789 € |
| Glaxosmithkline Investigacion y Desarrollo SL | 0,00 € |
| Helmholtz-Zentrum FUR Infektionsforschung GmbH | 1 431 355 € |
| Institut National de la Sante et de la Recherche Medicale | 86 126 € |
| Medizinische Universitaet Wien | 93 607 € |
| North Bristol National Health Service Trust | 2 350 273 € |
| Nosopharm | 4 050 626 € |
| Stichting Lygature | 931 575 € |
| The University of Liverpool | 1 504 294 € |
| Universite de Poitiers | 0,00 € |
https://cordis.europa.eu/project/id/853979
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
